Abstract: A class of compounds as a SGLT1/SGLT2/DPP4 triple inhibitor, and an application in preparation of a drug serving as the SGLT1/SGLT2/DPP4 triple inhibitor. Compounds represented by formula (I), and isomers and pharmaceutically-acceptable salts thereof are specifically involved.

Abstract: Disclosed are a solid form and a crystal form of a compound represented by formula (I) used as a BRD4 inhibitor, a preparation method therefor, and an application thereof in the preparation of a medicine for treating BRD4-related diseases. (I).

Abstract: The application relates to crystal forms of thienoimidazole compound and preparation method thereof, and use of the crystal forms in the preparation of a medicament for treating related diseases. Formula (II) compound, Formula (III) compound, Formula (IV) compound, Formula (V) compound, Formula (VI) compound, Formula (VII) compound and Formula (VIII) compound.

Abstract: A halogen-substituted pyridazinone compound and an application thereof. Specifically disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: A glucoside derivative that acts as an SGLT1 inhibitor and an application thereof in the preparation of a drug for SGLT1 related diseases. Specifically disclosed is a compound represented by formula (II), a tautomer thereof or a pharmaceutically acceptable composition thereof.

Abstract: A series of tricyclic compounds and the use thereof. Specifically disclosed are a compound as represented by formula (II) and a pharmaceutically acceptable salt thereof.

Abstract: A series of imidazocyclic compounds and an application thereof, which specifically relate to a compound represented by formula (P) and a pharmaceutically acceptable salt thereof.

Abstract: Thiazole-lactam-spiroheterocyclic compounds and applications thereof in the preparation of drugs for treating related diseases. Specifically disclosed are a compound as represented by formula (I) and pharmaceutically acceptable salts thereof.

Abstract: Provided are a dimethyl-substituted thiazololactam compound and the use thereof in the preparation of a drug for treating relevant diseases. Specifically, provided are a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof.

Abstract: A series of phenol compounds and the use thereof. Specifically disclosed are a compound as represented by formula (III) and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a class of macrocyclic derivatives, a preparation method therefor, a pharmaceutical composition containing the derivatives, and the use thereof as therapeutic agents, particularly as XIa factor inhibitors and in the preparation of a drug for treating and preventing thromboembolisms and other diseases. Particularly disclosed are compounds shown by formula (I), an isomer thereof and a pharmaceutically acceptable salt thereof.

Abstract: A crystal form of a fluorine-substituted pyridopyrazole compound and a preparation method thereof. Further provided is an application of the compound and the crystal form thereof in preparation of a drug for treating a related disease.

Abstract: Provided are a class of benzimidazole compounds and an application thereof as a 300/CBP inhibitor. Specifically, provided are a compound represented by formula (P) and a pharmaceutically acceptable salt thereof.

Abstract: The present application belongs to the field of medicine. In particular, the present application relates to a diarylthiohydantoin compound as an androgen receptor antagonist or a pharmaceutically acceptable salt thereof, a preparation method of the same, a pharmaceutical composition comprising the compound, and a use thereof in treating a cell proliferative disease mediated by androgen. The compound of the present application has good antagonistic effect on androgen receptor and exhibits excellent antitumor effect.

Abstract: Provided are crystal forms A, B, C and D of a compound of formula (I), and application of the crystal forms in the preparation of drugs for treating ASK1-related diseases.

Abstract: The present application relates to the field of medicine. Specifically, disclosed are a compound of formula (I), a preparation method therefor, and a pharmaceutical composition comprising the compound.

Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of furin, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of fibrotic diseases, including pulmonary fibrosis, renal fibrosis, liver fibrosis, skin fibrosis, ocular fibrosis, cardiac fibrosis, and other miscellaneous fibrotic conditions. The disclosed compounds may also be useful for treating other furin-mediated conditions, including but not limited to, hypertension, cancer, infectious diseases, and genetic disorders (e.g., cystic fibrosis (CF)), and neurodegenerative disorders.

Abstract: Disclosed are a class of BTK kinase inhibitor compounds with a high activity and a high selectivity and the use thereof in the preparation of a drug for treating BTK target-related diseases. Specifically, disclosed are a compound shown as formula (I), and an isomer and a pharmaceutically acceptable salt thereof.

Abstract: A novel five-membered heteroaromatic imidazole compound and use thereof is disclosed herein. Specifically, disclosed is a compound as shown in formula (III) or a pharmaceutically acceptable salt thereof. Also disclosed is a method for treating a disease related to GLP-1 receptor such as type II diabetes.

Abstract: The present application relates to the field of medicine. Specifically, disclosed are a compound of formula (I), a preparation method therefor, and a pharmaceutical composition comprising the compound.